Strong buy:
Quince Therapeutics, Inc. (QNCX) : 0.72 + 12.96%
52 Week Range 0.56 - 14.6000
September 30, 2022
Cash and cash equivalents $ 31,809
Short term investments 62,534
Prepaid expenses and other current assets 3,933
Total current assets 98,276
Property and equipment, net 375
Operating lease right-of-use assets, net 208
Long term investments 5,001
Intangible asset 5,900
Other assets 17
Total assets $ 109,777
Current liabilities:
Accounts payable $ 1,181
Accrued expenses and other current liabilities 3,764
Total current liabilities 4,945
Long-term financing lease liabilities 19
Long-term operating lease liabilities 34
Deferred tax liabilities 248
Total liabilities 5,246
As of December 27, the registrant had 36,130,306 shares of common stock
Total assets $ 109,777 - Total liabilities 5,246 : 36,130,306 shares of common stock = 2.894/ share.
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
